From: Antibody waning after immunosuppressive chemotherapy and immunomodulators, re-immunization considerations in pediatric patients with malignancy and chronic immune thrombocytopenic purpura
Seroprotection status (n, %)
Total
Partially protected
Fully susceptible*
Age category
2 to 5 years
36 (64.3%)
20 (35.7%)
56
5 to 10 years
38 (82.6%)
8 (17.4%)
46
> 10 years
6 (75%)
2 (25%)
8
80
30
110